RU2016147122A3 - - Google Patents

Download PDF

Info

Publication number
RU2016147122A3
RU2016147122A3 RU2016147122A RU2016147122A RU2016147122A3 RU 2016147122 A3 RU2016147122 A3 RU 2016147122A3 RU 2016147122 A RU2016147122 A RU 2016147122A RU 2016147122 A RU2016147122 A RU 2016147122A RU 2016147122 A3 RU2016147122 A3 RU 2016147122A3
Authority
RU
Russia
Application number
RU2016147122A
Other languages
Russian (ru)
Other versions
RU2016147122A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016147122A publication Critical patent/RU2016147122A/ru
Publication of RU2016147122A3 publication Critical patent/RU2016147122A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2221Relaxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • A61M5/14244Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/495Transforming growth factor [TGF]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/12Pulmonary diseases
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
RU2016147122A 2014-06-13 2015-06-10 Применение серелаксина для снижения gdf-15 RU2016147122A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462011744P 2014-06-13 2014-06-13
US62/011,744 2014-06-13
PCT/IB2015/054399 WO2015189790A1 (en) 2014-06-13 2015-06-10 Use of serelaxin to reduce gdf-15

Publications (2)

Publication Number Publication Date
RU2016147122A RU2016147122A (ru) 2018-07-16
RU2016147122A3 true RU2016147122A3 (enExample) 2019-01-28

Family

ID=53476944

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016147122A RU2016147122A (ru) 2014-06-13 2015-06-10 Применение серелаксина для снижения gdf-15

Country Status (11)

Country Link
US (2) US20170100460A1 (enExample)
EP (1) EP3154559B1 (enExample)
JP (1) JP6820748B2 (enExample)
KR (1) KR20170018829A (enExample)
CN (1) CN106413740A (enExample)
AU (2) AU2015273097A1 (enExample)
BR (1) BR112016028833A2 (enExample)
CA (1) CA2952061A1 (enExample)
MX (1) MX2016016414A (enExample)
RU (1) RU2016147122A (enExample)
WO (1) WO2015189790A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105658672A (zh) 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
EP4005585B1 (en) 2013-11-21 2024-03-27 The Brigham & Women's Hospital, Inc. Compositions and methods for treating right ventricular hypertrophy
CA2956256A1 (en) 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
CN116327952A (zh) 2015-08-04 2023-06-27 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
DK3628049T3 (da) 2017-05-04 2023-08-14 Acceleron Pharma Inc Tgf-beta-receptortype-ii-fusionsproteiner og anvendelser deraf
CN114025675A (zh) * 2019-06-20 2022-02-08 索尼集团公司 信息处理装置、信息处理方法和程序

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2660691C (en) * 2006-08-04 2020-01-14 Medizinische Hochschule Hannover Means and methods for assessing the risk of cardiac interventions based on gdf-15
ES2379104T3 (es) * 2007-05-24 2012-04-20 F. Hoffmann-La Roche Ag Métodos para evaluar el fallo cardíaco en pacientes con fibrilación auricular utilizando péptidos GDF-15
CA2724540C (en) * 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
MX2014000031A (es) * 2011-07-01 2014-07-09 Bayer Ip Gmbh Polipeptidos de fusion de relaxina y usos de los mismos.

Also Published As

Publication number Publication date
BR112016028833A2 (pt) 2017-08-22
MX2016016414A (es) 2017-04-10
CA2952061A1 (en) 2015-12-17
RU2016147122A (ru) 2018-07-16
AU2018202289A1 (en) 2018-04-26
JP2017519008A (ja) 2017-07-13
AU2015273097A1 (en) 2016-11-17
US20170100460A1 (en) 2017-04-13
CN106413740A (zh) 2017-02-15
JP6820748B2 (ja) 2021-01-27
EP3154559A1 (en) 2017-04-19
US20190022189A1 (en) 2019-01-24
WO2015189790A1 (en) 2015-12-17
KR20170018829A (ko) 2017-02-20
EP3154559B1 (en) 2021-09-01

Similar Documents

Publication Publication Date Title
BR112016017520A2 (enExample)
BR112016016951A2 (enExample)
BR112016016756A2 (enExample)
BR112016016478A2 (enExample)
BR112016016978A2 (enExample)
BR112016018948A2 (enExample)
BR112016018327A2 (enExample)
BR112016018868A2 (enExample)
BR112016018384A2 (enExample)
BR112016018278A2 (enExample)
BR112016018582A2 (enExample)
BR112016018556A2 (enExample)
BR112016015385A2 (enExample)
BR112016018865A2 (enExample)
BR112016017262A2 (enExample)
BR112016008129A2 (enExample)
BR112016016933A2 (enExample)
BR112016014460A2 (enExample)
BR112016017713A2 (enExample)
BR112016018944A2 (enExample)
BR112016000228A2 (enExample)
BR112016016534A2 (enExample)
BR112016018043A2 (enExample)
BR112016016601A2 (enExample)
BR112016015552A2 (enExample)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190610